NCT05263050 - Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions

Metastatic Renal Cell CarcinomaClear-cell Metastatic Renal Cell CarcinomaNeuroendocrine TumorsCarcinoid Tumor

Interventions

DRUG

Cabozantinib

Cabozantinib initiated at 40 mg daily. Dose-escalate or de-escalate based on pre-specified criteria and at set dosing schedules

DRUG

Nivolumab

Nivolumab injection is to be administered as an IV infusion at a dose of 480 mg on day 1 of each cycle

Trial Locations (1)

RECRUITING

Fox Chase Cancer Center, Philadelphia